Cardiac Overexpression of Angiotensin Converting Enzyme 2 Protects the Heart From Ischemia-Induced Pathophysiology
Open Access
- 1 March 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 51 (3), 712-718
- https://doi.org/10.1161/hypertensionaha.107.100693
Abstract
Angiotensin converting enzyme 2 (ACE2) has been linked to cardiac dysfunction and hypertension-induced cardiac pathophysiology. In this study, we used a gene overexpression approach to investigate the role of ACE2 in cardiac function and remodeling after myocardial infarction. Rats received an intracardiac injection of 4.5×10 8 lentivirus containing ACE2 cDNA, followed by permanent coronary artery ligation (CAL) of the left anterior descending artery. At 24 hours and 6 weeks after surgery, cardiac functions, viability, and pathophysiology were assessed by MRI) and by histological analysis. At 24 hours post-CAL, left ventricular (LV) anterior wall motion was stunted to the same extent in control CAL and lenti-ACE2–treated CAL rats. However lenti-ACE2–treated CAL rats showed a 60% reduction in delayed contrast-enhanced LV volume after gadodiamide injection, indicating early ischemic protection of myocardium by ACE2. At 6 weeks after CAL, lenti-ACE2 rats demonstrated a complete rescue of cardiac output, a 41% rescue of ejection fraction, a 44% rescue in contractility, a 37% rescue in motion, and a 53% rescue in LV anterior (infracted) wall thinning compared with control CAL rats. No changes were observed in the LV posterior (noninfarcted) wall other than an 81% rescue in motion produced by ACE2 in CAL rats. Finally, infarct size measured by 2,3,5-triphenyl-tetrazolium chloride staining was not significantly different between the ligated groups. These observations demonstrate that cardiac overexpression of ACE2 exerts protective influence on the heart during myocardial infarction by preserving cardiac functions, LV wall motion and contractility, and by attenuating LV wall thinning.Keywords
This publication has 29 references indexed in Scilit:
- Enalapril Attenuates Downregulation of Angiotensin-Converting Enzyme 2 in the Late Phase of Ventricular Dysfunction in Myocardial Infarcted RatHypertension, 2006
- ACE2: A novel therapeutic target for cardiovascular diseasesProgress in Biophysics and Molecular Biology, 2006
- Deletion of Angiotensin-Converting Enzyme 2 Accelerates Pressure Overload-Induced Cardiac Dysfunction by Increasing Local Angiotensin IIHypertension, 2006
- Angiotensin-Converting Enzyme II in the Heart and the KidneyCirculation Research, 2006
- Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1–7) in regulation of cardiovascular functionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Myocardial infarction increases ACE2 expression in rat and humansEuropean Heart Journal, 2005
- Interaction of ACE2 and integrin β1 in failing human heartBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2004
- ACE2 gene expression is up-regulated in the human failing heartBMC Medicine, 2004
- Increased Angiotensin-(1-7)–Forming Activity in Failing Human Heart VentriclesCirculation, 2003
- Angiotensin-converting enzyme 2 is an essential regulator of heart functionNature, 2002